Hybio Pharmaceutical Co., Ltd. (SHE:300199)
China · Delayed Price · Currency is CNY 22.12
+1.06 (5.03%)
Nov 3, 2025, 2:45 PM CST
Hybio Pharmaceutical Cash Flow Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2015 - 2019 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 | Dec '20 Dec 31, 2020 | 2015 - 2019 |
Net Income | -67.5 | -173.65 | -513.88 | -370.55 | 30.81 | -609.43 | Upgrade |
Depreciation & Amortization | 146.11 | 146.75 | 155.54 | 140.59 | 135.78 | 104.54 | Upgrade |
Other Amortization | 4.81 | 4.16 | 4.9 | 3.89 | 3.7 | 4.14 | Upgrade |
Loss (Gain) From Sale of Assets | -42.78 | -42.78 | 0.51 | -3.41 | -35.2 | 0.95 | Upgrade |
Asset Writedown & Restructuring Costs | 82.43 | 82.43 | 99.94 | 23.05 | 75.31 | 10.86 | Upgrade |
Loss (Gain) From Sale of Investments | -1.55 | -1.55 | -43.83 | 86.06 | -372.29 | -8.51 | Upgrade |
Provision & Write-off of Bad Debts | 5.55 | 5.55 | 2.96 | 35.95 | 70.22 | 424.52 | Upgrade |
Other Operating Activities | 212.57 | 136.1 | 166.02 | 142.83 | 127.31 | 78.19 | Upgrade |
Change in Accounts Receivable | 26.37 | 26.37 | 121.2 | -60.54 | 17.56 | 136.3 | Upgrade |
Change in Inventory | -80.07 | -80.07 | 20.98 | -57.7 | 19.28 | -42.37 | Upgrade |
Change in Accounts Payable | 78.32 | 78.32 | -17.12 | 59.6 | 81 | -65.12 | Upgrade |
Change in Other Net Operating Assets | -16.53 | -16.53 | -0.03 | 16.56 | - | - | Upgrade |
Operating Cash Flow | 347.34 | 164.71 | -3.54 | 15.81 | 156.83 | 47.99 | Upgrade |
Operating Cash Flow Growth | 150.17% | - | - | -89.92% | 226.79% | -54.14% | Upgrade |
Capital Expenditures | -218.45 | -115.84 | -81.76 | -189.85 | -199 | -243.66 | Upgrade |
Sale of Property, Plant & Equipment | 0.48 | 45.53 | 1.07 | 47.49 | 0.14 | 0.06 | Upgrade |
Cash Acquisitions | - | - | - | -0.1 | -3.92 | - | Upgrade |
Divestitures | 1.45 | - | - | -1.93 | - | - | Upgrade |
Investment in Securities | 7.07 | 0.3 | 228.37 | 195.29 | 21.2 | -15 | Upgrade |
Other Investing Activities | 2.67 | - | 0.03 | 0.82 | 3.19 | 0.14 | Upgrade |
Investing Cash Flow | -206.78 | -70.01 | 147.71 | 51.72 | -178.39 | -258.47 | Upgrade |
Short-Term Debt Issued | - | 190.4 | 12 | 5 | - | - | Upgrade |
Long-Term Debt Issued | - | 1,339 | 1,378 | 537.29 | 1,457 | 641.67 | Upgrade |
Total Debt Issued | 1,496 | 1,529 | 1,390 | 542.29 | 1,457 | 641.67 | Upgrade |
Short-Term Debt Repaid | - | -207.4 | - | - | - | - | Upgrade |
Long-Term Debt Repaid | - | -1,546 | -1,173 | -495.09 | -1,644 | -725.87 | Upgrade |
Total Debt Repaid | -1,584 | -1,753 | -1,173 | -495.09 | -1,644 | -725.87 | Upgrade |
Net Debt Issued (Repaid) | -87.61 | -224.15 | 216.25 | 47.2 | -187.81 | -84.21 | Upgrade |
Issuance of Common Stock | - | 2.14 | - | - | - | 45.05 | Upgrade |
Common Dividends Paid | -94.83 | -111.75 | -117.9 | -114.8 | -115.64 | -104.96 | Upgrade |
Other Financing Activities | 20.14 | -11.73 | -2.5 | -3.5 | 49.79 | 72.43 | Upgrade |
Financing Cash Flow | -162.3 | -345.48 | 95.85 | -71.11 | -253.67 | -71.68 | Upgrade |
Foreign Exchange Rate Adjustments | 3.31 | 3.38 | 0.92 | 2.07 | -1.58 | 1.93 | Upgrade |
Net Cash Flow | -18.42 | -247.4 | 240.94 | -1.51 | -276.81 | -280.22 | Upgrade |
Free Cash Flow | 128.89 | 48.87 | -85.3 | -174.04 | -42.17 | -195.67 | Upgrade |
Free Cash Flow Growth | 115.11% | - | - | - | - | - | Upgrade |
Free Cash Flow Margin | 14.35% | 8.28% | -19.77% | -24.71% | -5.73% | -27.11% | Upgrade |
Free Cash Flow Per Share | 0.15 | 0.06 | -0.10 | -0.20 | -0.04 | -0.21 | Upgrade |
Cash Income Tax Paid | - | 7.42 | 59.68 | 41.6 | 65.12 | 56.25 | Upgrade |
Levered Free Cash Flow | 36.6 | 59.65 | -54.53 | -176.94 | -190.2 | -113.19 | Upgrade |
Unlevered Free Cash Flow | 53.52 | 126.21 | 20.76 | -112.4 | -135.25 | -76.16 | Upgrade |
Change in Working Capital | 7.7 | 7.7 | 124.3 | -42.62 | 121.2 | 42.72 | Upgrade |
Updated Sep 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.